Wall St futures flat amid US-China trade jitters; bank earnings in focus
On Wednesday, BTIG analyst Ryan Zimmerman revised the price target for RxSight Inc. (NASDAQ:RXST) to $44.00, down from the previous $58.00, while maintaining a Buy rating on the stock. The revision comes as the company’s shares have declined nearly 48% over the past six months, though InvestingPro data shows the company maintains strong financial health with a current ratio of 12.67, indicating robust liquidity. Zimmerman’s adjustment followed the company’s fourth-quarter and full-year 2024 financial results, which were largely in line with BTIG and consensus estimates. RxSight reported fourth-quarter revenue of $40.2 million, marking a 41% year-over-year increase, and full-year revenue of $139.9 million, up 57% from the previous year.
The company’s performance was attributed to the sale of 83 Light Delivery Devices (LDDs) and 29,069 Light Adjustable Lenses (LALs) during the fourth quarter. This represented a 7.8% year-over-year and 6.4% quarter-over-quarter increase for LDDs, and a substantial 61% year-over-year and 18.4% quarter-over-quarter growth for LALs. According to InvestingPro, RxSight maintains an impressive gross profit margin of 68.44%, demonstrating strong operational efficiency. Get access to 6 more exclusive ProTips and comprehensive analysis with an InvestingPro subscription.
Looking forward, RxSight reaffirmed its fiscal year 2025 guidance, projecting revenues between $185 million and $197 million, which translates to a 32% to 41% year-over-year increase. The midpoint of this guidance, approximately $191 million, slightly exceeds the initial FY25 Street expectations of around $187.4 million.
Despite a deceleration in productivity growth from the mid-teens to 6.7% year-over-year, management expressed satisfaction with the progress of the LAL launch. RxSight has secured over 10% share in the premium market. For FY25, BTIG analysts anticipate that RxSight will continue to expand its LDD sales, with an estimated 8.9% increase in unit volumes, as the current install base represents only about 15% penetration in the broader physician population. Additionally, they expect a productivity growth of approximately 3.4% as market dynamics for cataract procedures improve.
These projections underpin BTIG’s FY25 estimates, which support a revenue compound annual growth rate (CAGR) of around 30%, significantly outpacing peers, and justifying a premium valuation for RxSight, according to Zimmerman. With a market capitalization of $1.17 billion and trailing twelve-month revenue growth of 67.52%, RxSight shows strong momentum despite current market challenges. Discover deeper insights and access the comprehensive Pro Research Report, available exclusively on InvestingPro, covering what really matters for over 1,400 top stocks.
In other recent news, Rxsight Inc. reported its fourth-quarter 2024 earnings, revealing an earnings per share (EPS) of $0.03, which significantly exceeded the forecasted EPS of -$0.17. The company’s revenue for the quarter was $40.2 million, slightly below the expected $40.39 million, but still representing a 41% increase year-over-year. Despite the revenue miss, the company improved its gross margin to 71.6% from 61.8% a year ago. Rxsight’s strategic initiatives included the expansion of its Light Adjustable Lenses (LALs) and Light Delivery Devices (LDDs), contributing to its robust growth. The company reported a net loss of $5.9 million, or $0.15 per share, but it ended the year with $237.2 million in cash and cash equivalents. Analyst firms such as BTIG and JPMorgan participated in the earnings call, reflecting the market’s interest in Rxsight’s performance and future potential. Rxsight has provided a revenue guidance range of $185-$197 million for 2025, indicating a growth rate of 32-41%. The company is also focusing on expanding its market reach internationally, with significant impacts anticipated by 2026.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.